Presentation is loading. Please wait.

Presentation is loading. Please wait.

P3.02b-017 Sequence of EGFR-TKI Therapy and BIM Deletion Polymorphism Affect the Outcome of Treatment in EGFR Positive NSCLC  Chanchai Charonpongsuntorn,

Published byOsborn Shields Modified over 5 years ago

Similar presentations

Presentation on theme: "P3.02b-017 Sequence of EGFR-TKI Therapy and BIM Deletion Polymorphism Affect the Outcome of Treatment in EGFR Positive NSCLC  Chanchai Charonpongsuntorn,"— Presentation transcript:

1 P3.02b-017 Sequence of EGFR-TKI Therapy and BIM Deletion Polymorphism Affect the Outcome of Treatment in EGFR Positive NSCLC  Chanchai Charonpongsuntorn, Pimpin Incharoen, Narumol Trachu, Dittapol Muntham, Kaettipong Kampreasart, Sakdiat Saowapa, Ekaphop Sirichainan, Thanyanan Reungwetwattana  Journal of Thoracic Oncology  Volume 12, Issue 1, (January 2017) DOI: /j.jtho Copyright © Terms and Conditions

2 Journal of Thoracic Oncology 2017 12, DOI: (10. 1016/j. jtho. 2016. 11
Copyright © Terms and Conditions

Download ppt "P3.02b-017 Sequence of EGFR-TKI Therapy and BIM Deletion Polymorphism Affect the Outcome of Treatment in EGFR Positive NSCLC  Chanchai Charonpongsuntorn,"

Similar presentations

P2.03b-044 Treatment Outcome and the Role of Primary Tumor Therapy in a Cohort of Patients with Synchronous Oligometastatic NSCLC  Jose Carlos Ruffinelli,

P2.03b-044 Treatment Outcome and the Role of Primary Tumor Therapy in a Cohort of Patients with Synchronous Oligometastatic NSCLC  Jose Carlos Ruffinelli,
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.
Journal of Thoracic Oncology  Volume 11, Issue 4, Pages (April 2016)

Journal of Thoracic Oncology  Volume 11, Issue 4, Pages (April 2016)
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
P3.02b-001 Phase 1 Dose Escalation of PF-06747775 (EGFR-T790M Inhibitor) in Patients with Advanced EGFRm (Del 19 or L858R+/-T790M) NSCLC  Hatim Husain,

P3.02b-001 Phase 1 Dose Escalation of PF (EGFR-T790M Inhibitor) in Patients with Advanced EGFRm (Del 19 or L858R+/-T790M) NSCLC  Hatim Husain,
SC09.04 Radiotherapy in China

SC09.04 Radiotherapy in China
P1.08-044 Comparison of Peri-Operative Outcomes after Robotic-Assisted Video- Thoracoscopic Lobectomies versus Segmentectomies  Maria Echavarria, Anna.

P Comparison of Peri-Operative Outcomes after Robotic-Assisted Video- Thoracoscopic Lobectomies versus Segmentectomies  Maria Echavarria, Anna.
Journal of Thoracic Oncology  Volume 12, Issue 3, Pages (March 2017)

Journal of Thoracic Oncology  Volume 12, Issue 3, Pages (March 2017)
P3.02b-029 Primary Double EGFR Mutations T790M and Mutation in Exon 19 or 21 - Prevalence and Treatment Results in Slovakian NSCLC Patients  Peter Berzinec,

P3.02b-029 Primary Double EGFR Mutations T790M and Mutation in Exon 19 or 21 - Prevalence and Treatment Results in Slovakian NSCLC Patients  Peter Berzinec,
P3.02b-016 An Exploration Study of Mechanisms Underlying Primary Resistance to EGFR-TKIs in Patients Harboring TKI-Sensitive EGFR Mutations  Ee Ke, Zhihong.

P3.02b-016 An Exploration Study of Mechanisms Underlying Primary Resistance to EGFR-TKIs in Patients Harboring TKI-Sensitive EGFR Mutations  Ee Ke, Zhihong.
MA12.09 Comparative Histological Subtype Analysis of Lung Adenocarcinoma Tumor and Metastatic Lymph Nodes and the Prognostic Impact  Shaohua Lu, Takashi.

MA12.09 Comparative Histological Subtype Analysis of Lung Adenocarcinoma Tumor and Metastatic Lymph Nodes and the Prognostic Impact  Shaohua Lu, Takashi.
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
Clinical Outcome of ALK-Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors.

Clinical Outcome of ALK-Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors.
P1.08-020 The Effect of Two Interventions on Attainment of Surgical Quality Measures in Resected Non-Small Cell Lung Cancer (NSCLC)  Nicholas Faris, Meredith.

P The Effect of Two Interventions on Attainment of Surgical Quality Measures in Resected Non-Small Cell Lung Cancer (NSCLC)  Nicholas Faris, Meredith.
OA20.03 Tumoral IL-7 Receptor is a Potential Target for Lung Adenocarcinoma Immunotherapy  Ming-Ching Lee, Takashi Eguchi, Zachary Tano, Kyuichi Kadota,

OA20.03 Tumoral IL-7 Receptor is a Potential Target for Lung Adenocarcinoma Immunotherapy  Ming-Ching Lee, Takashi Eguchi, Zachary Tano, Kyuichi Kadota,
P3.02a-036 Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK+ Metastatic NSCLC  Rafal Dziadziuszko,

P3.02a-036 Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK+ Metastatic NSCLC  Rafal Dziadziuszko,
P2.04-054 Pleural CEA and C-Reactive Protein in Patients with Lung Metastases and Malignant Pleural Effusion. A Prospective Case-Control Study  Franco.

P Pleural CEA and C-Reactive Protein in Patients with Lung Metastases and Malignant Pleural Effusion. A Prospective Case-Control Study  Franco.
Journal of Thoracic Oncology  Volume 12, Issue 5, Pages (May 2017)

Journal of Thoracic Oncology  Volume 12, Issue 5, Pages (May 2017)
Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green 

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green 

Similar presentations

Ads by Google